156 related articles for article (PubMed ID: 37595362)
1. PPM1D modulates hematopoietic cell fitness and response to DNA damage and is a therapeutic target in myeloid malignancy.
Miller PG; Sperling AS; Mayerhofer C; McConkey ME; Ellegast JM; Da Silva C; Cohen DN; Wang C; Sharda A; Yan N; Saha S; Schluter C; Schechter I; Słabicki M; Sandoval B; Kahn J; Boettcher S; Gibson CJ; Scadden DT; Stegmaier K; Bhatt S; Lindsley RC; Ebert BL
Blood; 2023 Dec; 142(24):2079-2091. PubMed ID: 37595362
[TBL] [Abstract][Full Text] [Related]
2. Ppm1d truncating mutations promote the development of genotoxic stress-induced AML.
Burocziova M; Danek P; Oravetzova A; Chalupova Z; Alberich-Jorda M; Macurek L
Leukemia; 2023 Nov; 37(11):2209-2220. PubMed ID: 37709843
[TBL] [Abstract][Full Text] [Related]
3. Reversal of the ATM/ATR-mediated DNA damage response by the oncogenic phosphatase PPM1D.
Lu X; Nguyen TA; Donehower LA
Cell Cycle; 2005 Aug; 4(8):1060-4. PubMed ID: 15970689
[TBL] [Abstract][Full Text] [Related]
4. Truncated PPM1D impairs stem cell response to genotoxic stress and promotes growth of APC-deficient tumors in the mouse colon.
Burocziova M; Burdova K; Martinikova AS; Kasparek P; Kleiblova P; Danielsen SA; Borecka M; Jenikova G; Janečková L; Pavel J; Zemankova P; Schneiderova M; Schwarzova L; Ticha I; Sun XF; Jiraskova K; Liska V; Vodickova L; Vodicka P; Sedlacek R; Kleibl Z; Lothe RA; Korinek V; Macurek L
Cell Death Dis; 2019 Oct; 10(11):818. PubMed ID: 31659152
[TBL] [Abstract][Full Text] [Related]
5. Protein phosphatase, Mg
Husby S; Hjermind Justesen E; Grønbæk K
Br J Haematol; 2021 Feb; 192(4):697-705. PubMed ID: 33616916
[TBL] [Abstract][Full Text] [Related]
6. Truncated PPM1D Prevents Apoptosis in the Murine Thymus and Promotes Ionizing Radiation-Induced Lymphoma.
Martinikova AS; Burocziova M; Stoyanov M; Macurek L
Cells; 2020 Sep; 9(9):. PubMed ID: 32927737
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of the DNA damage response phosphatase PPM1D reprograms neutrophils to enhance anti-tumor immune responses.
Uyanik B; Goloudina AR; Akbarali A; Grigorash BB; Petukhov AV; Singhal S; Eruslanov E; Chaloyard J; Lagorgette L; Hadi T; Baidyuk EV; Sakai H; Tessarollo L; Ryffel B; Mazur SJ; Lirussi F; Garrido C; Appella E; Demidov ON
Nat Commun; 2021 Jun; 12(1):3622. PubMed ID: 34131120
[TBL] [Abstract][Full Text] [Related]
8. Augmented cancer resistance and DNA damage response phenotypes in PPM1D null mice.
Nannenga B; Lu X; Dumble M; Van Maanen M; Nguyen TA; Sutton R; Kumar TR; Donehower LA
Mol Carcinog; 2006 Aug; 45(8):594-604. PubMed ID: 16652371
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of WIP1 phosphatase sensitizes breast cancer cells to genotoxic stress and to MDM2 antagonist nutlin-3.
Pechackova S; Burdova K; Benada J; Kleiblova P; Jenikova G; Macurek L
Oncotarget; 2016 Mar; 7(12):14458-75. PubMed ID: 26883108
[TBL] [Abstract][Full Text] [Related]
10. PPM1D mutations are oncogenic drivers of de novo diffuse midline glioma formation.
Khadka P; Reitman ZJ; Lu S; Buchan G; Gionet G; Dubois F; Carvalho DM; Shih J; Zhang S; Greenwald NF; Zack T; Shapira O; Pelton K; Hartley R; Bear H; Georgis Y; Jarmale S; Melanson R; Bonanno K; Schoolcraft K; Miller PG; Condurat AL; Gonzalez EM; Qian K; Morin E; Langhnoja J; Lupien LE; Rendo V; Digiacomo J; Wang D; Zhou K; Kumbhani R; Guerra Garcia ME; Sinai CE; Becker S; Schneider R; Vogelzang J; Krug K; Goodale A; Abid T; Kalani Z; Piccioni F; Beroukhim R; Persky NS; Root DE; Carcaboso AM; Ebert BL; Fuller C; Babur O; Kieran MW; Jones C; Keshishian H; Ligon KL; Carr SA; Phoenix TN; Bandopadhayay P
Nat Commun; 2022 Feb; 13(1):604. PubMed ID: 35105861
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of mutant PPM1D enhances DNA damage response and growth suppressive effects of ionizing radiation in diffuse intrinsic pontine glioma.
Akamandisa MP; Nie K; Nahta R; Hambardzumyan D; Castellino RC
Neuro Oncol; 2019 Jun; 21(6):786-799. PubMed ID: 30852603
[TBL] [Abstract][Full Text] [Related]
12. Gain-of-function mutations of PPM1D/Wip1 impair the p53-dependent G1 checkpoint.
Kleiblova P; Shaltiel IA; Benada J; Ševčík J; Pecháčková S; Pohlreich P; Voest EE; Dundr P; Bartek J; Kleibl Z; Medema RH; Macurek L
J Cell Biol; 2013 May; 201(4):511-21. PubMed ID: 23649806
[TBL] [Abstract][Full Text] [Related]
13. PPM1D Mutations Drive Clonal Hematopoiesis in Response to Cytotoxic Chemotherapy.
Hsu JI; Dayaram T; Tovy A; De Braekeleer E; Jeong M; Wang F; Zhang J; Heffernan TP; Gera S; Kovacs JJ; Marszalek JR; Bristow C; Yan Y; Garcia-Manero G; Kantarjian H; Vassiliou G; Futreal PA; Donehower LA; Takahashi K; Goodell MA
Cell Stem Cell; 2018 Nov; 23(5):700-713.e6. PubMed ID: 30388424
[TBL] [Abstract][Full Text] [Related]
14. The oncogenic phosphatase PPM1D confers cisplatin resistance in ovarian carcinoma cells by attenuating checkpoint kinase 1 and p53 activation.
Ali AY; Abedini MR; Tsang BK
Oncogene; 2012 Apr; 31(17):2175-86. PubMed ID: 21927021
[TBL] [Abstract][Full Text] [Related]
15.
Kahn JD; Miller PG; Silver AJ; Sellar RS; Bhatt S; Gibson C; McConkey M; Adams D; Mar B; Mertins P; Fereshetian S; Krug K; Zhu H; Letai A; Carr SA; Doench J; Jaiswal S; Ebert BL
Blood; 2018 Sep; 132(11):1095-1105. PubMed ID: 29954749
[TBL] [Abstract][Full Text] [Related]
16. PPM1D in Solid and Hematologic Malignancies: Friend and Foe?
Zhang L; Hsu JI; Goodell MA
Mol Cancer Res; 2022 Sep; 20(9):1365-1378. PubMed ID: 35657598
[TBL] [Abstract][Full Text] [Related]
17. A small molecule inhibitor of p53-inducible protein phosphatase PPM1D.
Yagi H; Chuman Y; Kozakai Y; Imagawa T; Takahashi Y; Yoshimura F; Tanino K; Sakaguchi K
Bioorg Med Chem Lett; 2012 Jan; 22(1):729-32. PubMed ID: 22115592
[TBL] [Abstract][Full Text] [Related]
18. Truncating mutations of PPM1D are found in blood DNA samples of lung cancer patients.
Zajkowicz A; Butkiewicz D; Drosik A; Giglok M; Suwiński R; Rusin M
Br J Cancer; 2015 Mar; 112(6):1114-20. PubMed ID: 25742468
[TBL] [Abstract][Full Text] [Related]
19. Chemical Inhibition of Wild-Type p53-Induced Phosphatase 1 (WIP1/PPM1D) by GSK2830371 Potentiates the Sensitivity to MDM2 Inhibitors in a p53-Dependent Manner.
Esfandiari A; Hawthorne TA; Nakjang S; Lunec J
Mol Cancer Ther; 2016 Mar; 15(3):379-91. PubMed ID: 26832796
[TBL] [Abstract][Full Text] [Related]
20. Mutant
Singh A; Mencia-Trinchant N; Griffiths EA; Altahan A; Swaminathan M; Gupta M; Gravina M; Tajammal R; Faber MG; Yan L; Sinha E; Hassane DC; Hayes DN; Guzman ML; Iyer R; Wang ES; Thota S
JCO Precis Oncol; 2022 Jan; 6():e2100309. PubMed ID: 35025619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
